Development, validation, and initial results of the Angioedema Activity Score
- 6 August 2013
- Vol. 68 (9), 1185-1192
- https://doi.org/10.1111/all.12209
Abstract
Background Recurrent angioedema (RecA) is a frequent clinical problem characterized by suddenly occurring cutaneous and/or mucosal swellings. Depending on their location, RecA may be painful, hindering, disfiguring, or even life‐threatening. The assessment of disease activity in affected patients is important to guide treatment decisions. Currently, however, there is no standardized and validated outcome measure available to do so. Objective To develop and validate the first specific patient‐reported outcome instrument to assess disease activity in RecA patients, the Angioedema Activity Score (AAS). Methods After a set of potential AAS items was developed, item evaluation and reduction were performed by means of impact analysis, factor analysis, regression analysis, and by checking for face validity. In addition, the items of the final AAS questionnaire were tested for their validity and reliability during a 12‐week validation study. Results In total, data from 110 and 80 RecA patients were used during the AAS item evaluation and validation phase, respectively. The resulting AAS consisted of five items and was found to have a one‐dimensional structure and excellent internal consistency. It correlated well with other measures of disease activity and quality‐of‐life impairment, thus demonstrating its convergent validity. In addition, the known‐groups validity and test–retest reliability of the AAS were found to be good. Conclusions The AAS is the first validated and reliable tool to determine disease activity in RecA patients, and it may serve as a valuable instrument in future clinical studies and routine patient care.Keywords
This publication has 22 references indexed in Scilit:
- Turkish Version of the Chronic Urticaria Quality of Life Questionnaire: Cultural Adaptation, Assessment of Reliability and ValidityActa Dermato Venereologica, 2012
- Improvement in health-related quality of life after therapy with omeprazole in patients with coronary artery disease and recurrent angina-like chest pain. A double-blind, placebo-controlled trial of the SF-36 surveyHealth and Quality of Life Outcomes, 2011
- Standard care impact on angioedema because of hereditary C1 inhibitor deficiency: a 21-month prospective study in a cohort of 103 patientsAllergy, 2010
- Hereditäres Angioödem: Update zu verfügbaren TherapieoptionenJDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2010
- Hereditary angioedema: an update on available therapeutic optionsJDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2010
- What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literatureJournal of the European Academy of Dermatology and Venereology, 2010
- The spectrum of chronic angioedemaAllergy and Asthma Proceedings, 2009
- How to assess disease activity in patients with chronic urticaria?Allergy, 2008
- Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidityBritish Journal of Dermatology, 2005
- A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU‐Q2oL)Allergy, 2005